Compare D Wave Quantum Inc (QBTS) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D Wave Quantum Inc vs BIO-TECHNE Corp — how do they compare? D Wave Quantum Inc trades at $14.91 (market cap $5.78B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while D Wave Quantum Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold D Wave Quantum Inc for 32 Days and BIO-TECHNE Corp for 63 Days on average.
| QBTS | TECH | |
|---|---|---|
Market Cap | $5.78B | $11.37B |
Volume | 14,335,003 | 3,153,511 |
Sector | Technology | Health |
52-Week High | $44.78 | $72.61 |
52-Week Low | $12.98 | $43.31 |
Typical Hold Time | 32 Days | 63 Days |
Enterprise Value | $5.28B | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QBTS (D-Wave Quantum Inc.) trades at $15.22, down 3.61% on the day, amid a bearish technical signal despite a 100% analyst buy rating with a consensus price target of $34.38. The company shows significant financial strain with a net income margin of -2,001.59% and negative cash flow from operations, though it maintains a high gross margin of 64.19%. Recent news highlights ongoing fraud investigations alongside technological advancements in quantum computing.
The stock presents high risk due to severe losses and cash burn, but offers speculative upside if the company can monetize its quantum technology. Investors face substantial volatility from operational challenges and legal scrutiny, requiring caution despite Wall Street optimism.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
